Grzegorz G.
- Country
- Poland
- Department
- N/A
Research Overview
- A Phase 2a Study to Evaluate the Safety and Efficacy of ABBV-142 in Adults with Idiopathic Pulmonary Fibrosis
- Therapeutic Equivalence of CHF5993 Combination Therapy Using HFA-152a Versus HFA-134a in Adults With Mild to Moderate Asthma
- Efficacy and Safety of Early Depemokimab Initiation as Add-on Therapy in Patients with Chronic Obstructive Pulmonary Disease and Type 2 Inflammation
Data & Insights
Has run more than one trial at 346 of 805 partner sites.
Specializations
Asthma and Type 2 inflammation
Clinical research activity is centered on moderate-to-severe asthma, oral corticosteroid-dependent asthma, severe and inadequately controlled asthma, and mild to moderate asthma. The therapeutic focus includes control of airway inflammation, reduction of exacerbations, and improvement of lung function in patients with persistent symptoms.
- Inhaled triple therapy for asthma control
- Oral corticosteroid reduction
- Asthma exacerbation prevention
- Type 2 inflammatory pathways
Work in this area also includes interest in treatment options for patients with eosinophilic inflammation and poorly controlled disease.
Chronic obstructive pulmonary disease
A major part of the clinical portfolio concerns COPD, including moderate-to-severe COPD, chronic bronchitis, and COPD with frequent exacerbations. The therapeutic landscape emphasizes maintenance bronchodilation, exacerbation reduction, and cardiopulmonary outcomes.
- Triple inhaled therapy in COPD
- Exacerbation reduction
- Lung function improvement
- Cardiopulmonary outcomes
Research involvement also extends to COPD populations with a history of exacerbations and former smokers requiring long-term disease control.
Interstitial lung disease and pulmonary fibrosis
The investigator is involved in studies of idiopathic pulmonary fibrosis and systemic sclerosis-associated interstitial lung disease, with attention to progressive fibrotic lung disease and preservation of respiratory function.
- Fibrotic lung disease
- Forced vital capacity
- Antifibrotic therapy
- Interstitial lung impairment
This area includes therapeutic interest in disease modification and symptom burden in chronic fibrosing conditions.
Bronchiectasis, respiratory syncytial virus, and acute respiratory infections
Clinical trial activity also covers bronchiectasis and respiratory syncytial virus (RSV) infection, reflecting a focus on airway infection, mucus-related disease, and acute respiratory complications in vulnerable adults.
- Bronchiectatic airway disease
- RSV infection
- Respiratory symptom progression
- Complication prevention
Interest in this domain aligns with management of chronic airway damage and infectious triggers of respiratory decline.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.